Risk Prediction Model of MACE in Patients With AMI Based on Multi-modal Machine Learning

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Jan 5, 2025

Keywords

ClinConnect Summary

This clinical trial is looking to develop a risk prediction model for serious heart events (known as Major Adverse Cardiac Events, or MACE) in patients who have had a heart attack (called Acute Myocardial Infarction, or AMI). The study will take place at Jiangsu Provincial People's Hospital and 13 other hospitals, and it aims to gather important information by following patients for a year after they receive treatment. The goal is to use advanced technology, called multi-modal machine learning, to better understand which patients are at higher risk for these serious outcomes.

To participate in the trial, individuals must be between 18 and 75 years old and diagnosed with a heart attack. They should also be eligible for an emergency procedure called PCI (Percutaneous Coronary Intervention) and be willing to undergo this treatment. Participants will receive consistent medication after their procedure and will be monitored for 12 months. However, those with certain health issues, such as severe infections, blood diseases, or other significant heart conditions, will not be eligible. This study is important as it aims to improve care and outcomes for heart attack patients by predicting risks more accurately.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Meeting the diagnostic criteria of AMI;
• • Ages 18 - 75 years old;
• • Meeting the indications for emergency PCI surgery, with informed consent and voluntarily undergoing PCI treatment; ④ Accurate and complete clinical relevant data; ⑤ First diagnosis and treatment; ⑥ All patients were given unified antiplatelet therapy after the operation; ⑦ All patients were followed up for 12 months after the operation.
• Exclusion Criteria:
• • With malignant tumors, infections and other diseases;
• • Blood diseases, immune system diseases, severe liver and kidney function disorders; ③ With other heart diseases such as heart failure; ④ Patients undergoing surgical treatment.